(Reuters) - It "would strengthen FDA's post-marketing drug safety authority, provide greater transparency" among other changes, House Energy and Commerce Health Subcommittee Chairman Rep. Frank Pallone said in a letter dated June 6.
The panel plans to hold a hearing on the legislation June 12 and vote on the bill June 14, the New Jersey Democrat said.
Read more at Reuters.com Government Filings News
The panel plans to hold a hearing on the legislation June 12 and vote on the bill June 14, the New Jersey Democrat said.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment